GLP-1受体激动剂与非动脉炎性前部缺血性视神经病变:内分泌科医生须知
本文综述了GLP-1受体激动剂(GLP-1 RA)与非动脉炎性前部缺血性视神经病变(NAION)可能关联的新证据。回顾性队列研究显示暴露组与非暴露组风险比范围为2.19至7.74。结论认为绝对风险仍低,需权衡GLP-1 RA的明确获益,并需进一步研究识别高危患者特征。
要点
- GLP-1 RA与NAION可能存在关联,但绝对风险低。
- 回顾性队列研究风险比范围2.19至7.74。
- 需平衡GLP-1 RA的已知显著获益与潜在风险。
核心结论
- 新兴证据提示GLP-1 RA启用与NAION可能存在关联,但绝对风险仍低,需与GLP-1 RA的已知显著获益相平衡。
研究设计与样本
- 本文为综述,探讨GLP-1 RA在2型糖尿病和肥胖患者中与NAION风险相关的研究。
主要发现
- 支持关联的回顾性队列研究报告风险比范围为2.19至7.74(暴露组 vs 非暴露组)。
临床怎么用
- 内分泌科医生处方GLP-1 RA时应知晓NAION的潜在风险,但无需因绝对风险低而回避使用。
局限性
- 需进一步研究视盘参数、血压变化、体重减轻程度或血糖控制改善等患者特征是否有助于识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There is emerging evidence suggesting a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) and non-arteritic anterior ischemic optic neuropathy (NAION). Retrospective cohort studies supporting this association report hazard ratios ranging from 2.19 to 7.74 when comparing exposed vs unexposed groups. This article explores the current research surrounding the risk of NAION with GLP-1 RA use in patients with type 2 diabetes and obesity, analyses patient factors that may increase susceptibility and highlights key areas warranting further research to guide endocrinologists in future prescribing. CONCLUSION: Whilst the emerging evidence suggests a possible association between commencement of GLP-1 RAs and NAION, absolute risk remains low and needs to be balanced with the known substantial benefits of GLP-1 RAs. Further research is needed to investigate whether specific patient characteristics such as optic disc parameters, blood pressure changes, degree of weight loss, or improvement of glycemic control can assist clinicians in identifying those at higher risk.
引用
- Liu L, Mohan S, Wu L, et al. GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy: What an Endocrinologist Needs to Know. J Clin Endocrinol Metab. 2025. PMID: 41022666. doi:10.1210/clinem/dgaf541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。